한글목차

희귀의약품 시장은 2030년까지 9,590억 달러에 달할 전망입니다.

2023년에 3,617억 달러로 평가된 희귀의약품 시장은 2030년에는 9,590억 달러에 이를 전망이며, 예측 기간 동안 복합 연간 성장률(CAGR) 14.9%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 생물 제제는 복합 연간 성장률(CAGR) 15.5%로 성장을 지속하고, 분석 기간 종료 시 6,123억 달러에 달할 것으로 예측됩니다. 비생물학적 제형 유형의 부문은 분석 기간 동안 복합 연간 성장률(CAGR) 14.0%에서 성장할 것으로 추정됩니다.

미국 시장은 992억 달러를 나타낼 전망이며 중국은 복합 연간 성장률(CAGR) 14.1%로 성장할 것으로 예측됩니다.

미국의 희귀의약품 시장은 2023년에 992억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 1,455억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR) 14.1%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 13.2%와 12.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 10.7%로 성장할 것으로 예측됩니다.

세계 희귀 질병용 의약품 시장 - 주요 동향과 촉진요인 요약

언메트 메디컬 니즈에 대응하는데 필수적인 언메트 키워드는 특히 개발 비용이 높고 환자 수가 제한되어 있기 때문에 종래 시장 개척에서는 커버할 수 없었던 희귀질환을 타겟으로 하고 있습니다. 이러한 의약품은 잠재적 수익이 수,000만 달러에 달하는 거액의 투자를 정당화할 수 없을 정도로 희귀한 질환을 대상으로 설계되어 있으며 분자 발견부터 시장 승인까지 10년 이상 걸리는 것이 일반적 적입니다. 이러한 과제에도 불구하고, 희귀의약품은 공중 보건에 중요한 역할을 하고 있으며, 종종 치료의 유일한 희망을 제공합니다. 또한 이러한 의약품은 일반적인 질병에 대한 기존의 치료법을 재사용하여 보다 드문 적응증으로 확대된 것일 수 있어 치료 범위와 유용성을 높여줍니다.

희소질병용 의약품의 개발과 지원은 1983년 미국에서 도입된 희소질병용 의약품법(Orphan Drug Act)을 비롯한 법적 틀에 의해 크게 형성되어 왔습니다. 이 법은 세계적으로 유사한 정책과 함께 세액 공제, 수수료 감면, 시장 독점권 연장 등 희귀질환의 치료 개발을 자극하는 다양한 인센티브를 제공합니다. 이러한 질병은 인구의 극히 일부, 일반적으로 2000명 중 1명 이하의 비율로 고통받으며 세계 수백만 명에 영향을 미치는 방대한 질병의 대표입니다. 이 법적 지원은 희귀의약품의 개발을 경제적으로 실행할 수 있게 하고 제약회사가 통상이라면 ROI의 전망이 부족하기 때문에 피할 연구분야에 투자하도록 장려합니다. 목적입니다.

미래를 바라보면, 희귀의약품의 영역은 첨단 기술의 통합이 진행되고 규제 상황이 변화함에 따라 확대해 나갈 것입니다. 유전자 연구와 생명 공학의 진보로 희귀질환의 분자 수준에서의 식별과 이해가 비약적으로 진행되어 표적 치료의 개발이 용이해졌습니다. 개인화된 의료를 향한 움직임은 개인의 유전자 프로파일에 맞는 정밀 치료의 한계를 계속 넓혀 환자의 결과를 크게 개선하고 있습니다. 또한 FDA 및 EMA와 같은 기관이 제공하는 규제 우대 조치 및 신속한 승인 프로세스는 희귀 질병 의약품 개발을 촉진하는 데 매우 중요합니다. 공동 연구 이니셔티브와 혁신적인 자금 제공 모델도 매우 중요하며 경제적 부담을 줄이고 보다 신속한 연구 개발을 촉진합니다. 희귀의약품에 대한 수요가 높아지고 있으며, 이 중요한 건강 관리 분야에서 지속적인 기술 혁신과 지원의 중요성이 강조되고 있습니다.

조사 대상 기업 예(전 18건)

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Alexion Pharmaceuticals Inc.
• Amgen Inc.
• AstraZeneca Plc.
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corp.
• CEL-SCI Corporation
• Concordia International Corp.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genzyme Corp.,
• Johnson & Johnson
• Merck & Co. Inc.
• Merck Serono SA
• Novartis AG
• Pfizer Inc.
• Recordati SpA
• Sanofi SA
• Shire Plc.
• Vertex Pharmaceuticals

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Orphan Drugs Market to Reach US$959.0 Billion by 2030

The global market for Orphan Drugs estimated at US$361.7 Billion in the year 2023, is expected to reach US$959.0 Billion by 2030, growing at a CAGR of 14.9% over the analysis period 2023-2030. Biologics Drug Type, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$612.3 Billion by the end of the analysis period. Growth in the Non-Biologics Drug Type segment is estimated at 14.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$99.2 Billion While China is Forecast to Grow at 14.1% CAGR

The Orphan Drugs market in the U.S. is estimated at US$99.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$145.5 Billion by the year 2030 trailing a CAGR of 14.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 12.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

Global Orphan Drugs Market - Key Trends and Drivers Summarized

Orphan drugs are vital in addressing unmet medical needs, specifically targeting rare diseases that traditional market incentives fail to cover due to high development costs and limited patient populations. These drugs are designed for conditions so rare that the potential revenue does not typically justify the enormous investment required, which can reach tens of millions and involve a decade-long journey from molecule discovery to market approval. Despite these challenges, orphan drugs play a critical role in public health, offering the only hope for treatment in many cases. These drugs may also be repurposed versions of existing treatments for common diseases, broadened to cover rarer indications, thus enhancing their therapeutic scope and utility.

The development and support for orphan drugs have been significantly shaped by legislative frameworks, notably the Orphan Drug Act introduced in the United States in 1983. This act, along with similar policies globally, provides various incentives such as tax credits, reduced fees, and extended market exclusivity to stimulate the development of treatments for rare diseases. These diseases affect a tiny fraction of the population, typically fewer than one person per 2000, representing a vast array of conditions that impact millions worldwide. The legislative support aims to make the development of orphan drugs economically viable and encourages pharmaceutical companies to invest in research areas they would likely avoid due to poor ROI prospects under normal circumstances.

Looking to the future, the realm of orphan drugs is set to expand with the growing integration of advanced technologies and shifting regulatory landscapes. Advances in genetic research and biotechnology have dramatically enhanced the identification and understanding of rare diseases at a molecular level, facilitating the development of targeted treatments. The movement towards personalized medicine continues to push the boundaries of precision therapies, tailored to individual genetic profiles, significantly improving patient outcomes. Furthermore, regulatory incentives and fast-track approval processes provided by entities such as the FDA and EMA are crucial in encouraging the development of orphan drugs. Collaborative research initiatives and innovative funding models are also pivotal, reducing the financial burden and fostering faster drug development. As awareness and advocacy grow, so does the support for addressing the unique challenges posed by rare diseases, thereby driving the demand for orphan drugs and underlining the importance of continued innovation and support in this crucial healthcare sector.

Select Competitors (Total 18 Featured) -

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Alexion Pharmaceuticals Inc.
• Amgen Inc.
• AstraZeneca Plc.
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corp.
• CEL-SCI Corporation
• Concordia International Corp.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genzyme Corp.,
• Johnson & Johnson
• Merck & Co. Inc.
• Merck Serono SA
• Novartis AG
• Pfizer Inc.
• Recordati S.p.A.
• Sanofi SA
• Shire Plc.
• Vertex Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Orphan Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Rare Diseases
  • Growth of Biopharmaceutical Industry
  • Advancements in Genetic and Molecular Research
  • Rising Adoption of Personalized Medicine
  • Impact of COVID-19 Pandemic on Orphan Drug Development
  • Government Regulations and Incentives for Orphan Drugs
  • Expansion of Orphan Drug Applications in Various Therapeutic Areas
  • Development of Novel Drug Delivery Systems for Orphan Drugs
  • Consumer Preferences for Innovative and Effective Treatments
  • Role of Orphan Drugs in Enhancing Patient Outcomes and Quality of Life
  • Market Penetration of Orphan Drugs in Developing Regions
  • Influence of Technological Innovations on Orphan Drug Development
  • Growth of Orphan Drugs in Oncology and Rare Genetic Disorders
  • Emerging Markets and Growth Opportunities in Developing Regions
  • Future Trends and Innovations in Orphan Drug Research and Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• JAPAN
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• CHINA
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• EUROPE
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• FRANCE
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: France 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: France 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• GERMANY
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Germany 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Italy 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: UK 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of World 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
  • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Rest of World 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

IV. COMPETITION